Biotech News

Absci Launches ABS-201 Endometriosis Advisory Board with Leading Experts from Yale, UCSF, Duke, and the Mayo Clinic

Absci Corporation (ABSI)Absci CorporationCompany update

Experts at the forefront of reproductive medicine, fertility, and translational research will guide the clinical research program for a new therapeutic antibody treatment VANCOUVER, Wash. and NEW YORK, March 24, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ: ABSI), a clinical-stage

Related news

Absci Corporation

AI-Enabled Biologic Design Absci combines generative artificial intelligence with high-throughput synthetic biology to design and validate novel biologics. Its integrated platform repeatedly feeds laboratory results back into computational models. ABS-201 ABS-201 is a long-acting antibody against the prolactin receptor. Its...

Recent company news

Stock data

Close
8.30 USD
Market cap
990M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States